NORMALIZED SECTIONS {'list of tables': 'LIST OF TABLES PAGEREF _Toc68776447 \\h 8', '1 protocol summary': '1. PROTOCOL SUMMARY PAGEREF _Toc68776448 \\h 9', '11 synopsis': '1.1. Synopsis PAGEREF _Toc68776449 \\h 9', '12 schema': '1.2. Schema PAGEREF _Toc68776450 \\h 13', '13 schedule of activities': '1.3. Schedule of Activities PAGEREF _Toc68776451 \\h 14', '2 introduction': '2. INTRODUCTION PAGEREF _Toc68776452 \\h 16', '21 pneumococcal disease': '2.1. Pneumococcal Disease PAGEREF _Toc68776453 \\h 16', '22 vaccines to prevent pneumococcal disease': '2.2. Vaccines to Prevent Pneumococcal Disease PAGEREF _Toc68776454 \\h 16', '221 pneumococcal polysaccharide vaccines': '2.2.1. Pneumococcal Polysaccharide Vaccines PAGEREF _Toc68776455 \\h 16', '222 pneumococcal polysaccharide conjugate vaccines': '2.2.2. Pneumococcal Polysaccharide Conjugate Vaccines PAGEREF _Toc68776456 \\h 17', '23 development of 20vpnc': '2.3. Development of 20vPnC PAGEREF _Toc68776457 \\h 18', '24 indication': '2.4. Indication PAGEREF _Toc68776458 \\h 19', '25 coronavirus disease 2019 covid19': '2.5. Coronavirus Disease 2019 (COVID19) PAGEREF _Toc68776459 \\h 19', '26 study rationale': '2.6. Study Rationale PAGEREF _Toc68776460 \\h 20', '27 background': '2.7. Background PAGEREF _Toc68776461 \\h 20', '271 clinical overview': '2.7.1. Clinical Overview PAGEREF _Toc68776462 \\h 21', '28 benefitrisk assessment': '2.8. Benefit/Risk Assessment PAGEREF _Toc68776463 \\h 21', '281 risk assessment': '2.8.1. Risk Assessment PAGEREF _Toc68776464 \\h 23', '282 benefit assessment': '2.8.2. Benefit Assessment PAGEREF _Toc68776465 \\h 25', '283 overall benefitrisk conclusion': '2.8.3. Overall Benefit/Risk Conclusion PAGEREF _Toc68776466 \\h 25', '3 objectives endpoints and estimands': '3. OBJECTIVES, ENDPOINTS, and estimands PAGEREF _Toc68776467 \\h 25', '4 study design': '4. STUDY DESIGN PAGEREF _Toc68776468 \\h 26', '41 overall design': '4.1. Overall Design PAGEREF _Toc68776469 \\h 26', '42 scientific rationale for study design': '4.2. Scientific Rationale for Study Design PAGEREF _Toc68776470 \\h 28', '421 diversity of study population': '4.2.1. Diversity of Study Population PAGEREF _Toc68776471 \\h 28', '422 choice of contraceptionbarrier requirements': '4.2.2. Choice of Contraception/Barrier Requirements PAGEREF _Toc68776472 \\h 28', '43 justification for dose': '4.3. Justification for Dose PAGEREF _Toc68776473 \\h 29', '44 end of study definition': '4.4. End of Study Definition PAGEREF _Toc68776474 \\h 29', '5 study population': '5. STUDY POPULATION PAGEREF _Toc68776475 \\h 29', '51 inclusion criteria': '5.1. Inclusion Criteria PAGEREF _Toc68776476 \\h 29', '52 exclusion criteria': '5.2. Exclusion Criteria PAGEREF _Toc68776477 \\h 31', '53 lifestyle considerations': '5.3. Lifestyle Considerations PAGEREF _Toc68776478 \\h 32', '531 contraception': '5.3.1. Contraception PAGEREF _Toc68776479 \\h 32', '54 screen failures': '5.4. Screen Failures PAGEREF _Toc68776480 \\h 33', '55 criteria for temporarily delaying enrollmentrandomizationadministration of study intervention': '5.5. Criteria for Temporarily Delaying Enrollment/Randomization/Administration of Study Intervention PAGEREF _Toc68776481 \\h 33', '6 study interventions and concomitant therapy': '6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY PAGEREF _Toc68776482 \\h 33', '61 study interventions administered': '6.1. Study Intervention(s) Administered PAGEREF _Toc68776483 \\h 33', '611 administration': '6.1.1. Administration PAGEREF _Toc68776484 \\h 34', '612 medical devices': '6.1.2. Medical Devices PAGEREF _Toc68776485 \\h 35', '62 preparation handling storage and accountability': '6.2. Preparation, Handling, Storage, and Accountability PAGEREF _Toc68776486 \\h 35', '621 preparation and dispensing': '6.2.1. Preparation and Dispensing PAGEREF _Toc68776487 \\h 36', '63 measures to minimize bias randomization and blinding': '6.3. Measures to Minimize Bias: Randomization and Blinding PAGEREF _Toc68776488 \\h 37', '631 allocation to study intervention': '6.3.1. Allocation to Study Intervention PAGEREF _Toc68776489 \\h 37', '632 blinding of site personnel': '6.3.2. Blinding of Site Personnel PAGEREF _Toc68776490 \\h 37', '633 blinding of the sponsor': '6.3.3. Blinding of the Sponsor PAGEREF _Toc68776491 \\h 38', '634 breaking the blind': '6.3.4. Breaking the Blind PAGEREF _Toc68776492 \\h 38', '64 study intervention compliance': '6.4. Study Intervention Compliance PAGEREF _Toc68776493 \\h 38', '65 dose modification': '6.5. Dose Modification PAGEREF _Toc68776494 \\h 39', '66 continued access to study intervention after the end of the study': '6.6. Continued Access to Study Intervention After the End of the Study PAGEREF _Toc68776495 \\h 39', '67 treatment of overdose': '6.7. Treatment of Overdose PAGEREF _Toc68776496 \\h 39', '68 concomitant therapy': '6.8. Concomitant Therapy PAGEREF _Toc68776497 \\h 39', '681 prohibited during the study': '6.8.1. Prohibited During the Study PAGEREF _Toc68776498 \\h 39', '682 permitted during the study': '6.8.2. Permitted During the Study PAGEREF _Toc68776499 \\h 40', '7 discontinuation of study intervention and participant discontinuationwithdrawal': '7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL PAGEREF _Toc68776500 \\h 40', '71 discontinuation of study intervention': '7.1. Discontinuation of Study Intervention PAGEREF _Toc68776501 \\h 40', '72 participant discontinuationwithdrawal from the study': '7.2. Participant Discontinuation/Withdrawal From the Study PAGEREF _Toc68776502 \\h 40', '721 withdrawal of consent': '7.2.1. Withdrawal of Consent PAGEREF _Toc68776503 \\h 41', '73 lost to followup': '7.3. Lost to FollowUp PAGEREF _Toc68776504 \\h 42', '8 study assessments and procedures': '8. STUDY ASSESSMENTS AND PROCEDURES PAGEREF _Toc68776505 \\h 42', '81 efficacy andor immunogenicity assessments': '8.1. Efficacy and/or Immunogenicity Assessments PAGEREF _Toc68776506 \\h 43', '811 immunogenicity assessments': '8.1.1. Immunogenicity Assessments PAGEREF _Toc68776507 \\h 43', '812 biological samples': '8.1.2. Biological Samples PAGEREF _Toc68776508 \\h 44', '82 safety assessments': '8.2. Safety Assessments PAGEREF _Toc68776509 \\h 44', '821 participant electronic diary': '8.2.1. Participant Electronic Diary PAGEREF _Toc68776510 \\h 44', '822 grading scale for prompted events': '8.2.2. Grading Scale for Prompted Events PAGEREF _Toc68776511 \\h 45', '8221 local reactions': '8.2.2.1. Local Reactions PAGEREF _Toc68776512 \\h 45', '8222 systemic events systemic symptoms and fever': '8.2.2.2. Systemic Events – Systemic Symptoms and Fever PAGEREF _Toc68776513 \\h 46', '8223 use of antipyreticpain medication': '8.2.2.3. Use of Antipyretic/Pain Medication PAGEREF _Toc68776514 \\h 48', '823 clinical safety laboratory assessments': '8.2.3. Clinical Safety Laboratory Assessments PAGEREF _Toc68776515 \\h 48', '83 adverse events serious adverse events and other safety reporting': '8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting PAGEREF _Toc68776516 \\h 48', '831 time period and frequency for collecting ae and sae information': '8.3.1. Time Period and Frequency for Collecting AE and SAE Information PAGEREF _Toc68776517 \\h 49', '8311 reporting saes to pfizer safety': '8.3.1.1. Reporting SAEs to Pfizer Safety PAGEREF _Toc68776518 \\h 49', '8312 recording nonserious aes and saes on the crf': '8.3.1.2. Recording Nonserious AEs and SAEs on the CRF PAGEREF _Toc68776519 \\h 50', '832 method of detecting aes and saes': '8.3.2. Method of Detecting AEs and SAEs PAGEREF _Toc68776520 \\h 50', '833 followup of aes and saes': '8.3.3. FollowUp of AEs and SAEs PAGEREF _Toc68776521 \\h 50', '834 regulatory reporting requirements for saes': '8.3.4. Regulatory Reporting Requirements for SAEs PAGEREF _Toc68776522 \\h 50', '835 environmental exposure exposure during pregnancy or breastfeeding and occupational exposure': '8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and Occupational Exposure PAGEREF _Toc68776523 \\h 51', '8351 exposure during pregnancy': '8.3.5.1. Exposure During Pregnancy PAGEREF _Toc68776524 \\h 51', '8352 exposure during breastfeeding': '8.3.5.2. Exposure During Breastfeeding PAGEREF _Toc68776525 \\h 53', '8353 occupational exposure': '8.3.5.3. Occupational Exposure PAGEREF _Toc68776526 \\h 53', '836 cardiovascular and death events': '8.3.6. Cardiovascular and Death Events PAGEREF _Toc68776527 \\h 53', '837 diseaserelated events andor diseaserelated outcomes not qualifying as aes or saes': '8.3.7. DiseaseRelated Events and/or DiseaseRelated Outcomes Not Qualifying as AEs or SAEs PAGEREF _Toc68776528 \\h 53', '838 adverse events of special interest': '8.3.8. Adverse Events of Special Interest PAGEREF _Toc68776529 \\h 54', '8381 lack of efficacy': '8.3.8.1. Lack of Efficacy PAGEREF _Toc68776530 \\h 54', '839 medical device deficiencies': '8.3.9. Medical Device Deficiencies PAGEREF _Toc68776531 \\h 54', '8391 time period for detecting medical device deficiencies': '8.3.9.1. Time Period for Detecting Medical Device Deficiencies PAGEREF _Toc68776532 \\h 54', '8392 followup of medical device deficiencies': '8.3.9.2. FollowUp of Medical Device Deficiencies PAGEREF _Toc68776533 \\h 54', '8393 prompt reporting of device deficiencies to the sponsor': '8.3.9.3. Prompt Reporting of Device Deficiencies to the Sponsor PAGEREF _Toc68776534 \\h 55', '8394 regulatory reporting requirements for device deficiencies': '8.3.9.4. Regulatory Reporting Requirements for Device Deficiencies PAGEREF _Toc68776535 \\h 55', '8310 medication errors': '8.3.10. Medication Errors PAGEREF _Toc68776536 \\h 55', '84 pharmacokinetics': '8.4. Pharmacokinetics PAGEREF _Toc68776537 \\h 56', '85 genetics': '8.5. Genetics PAGEREF _Toc68776538 \\h 56', '86 biomarkers': '8.6. Biomarkers PAGEREF _Toc68776539 \\h 57', '87 immunogenicity assessments': '8.7. Immunogenicity Assessments PAGEREF _Toc68776540 \\h 57', '88 health economics': '8.8. Health Economics PAGEREF _Toc68776541 \\h 57', '89 study procedures': '8.9. Study Procedures PAGEREF _Toc68776542 \\h 57', '891 visit 1 day 1': '8.9.1. Visit 1 (Day 1) PAGEREF _Toc68776543 \\h 57', '892 visit 2 21 to 35 days after visit 1': '8.9.2. Visit 2 (21 to 35 Days After Visit 1) PAGEREF _Toc68776544 \\h 60', '893 visit 3 6 months 168 to 196 days after visit 1': '8.9.3. Visit 3 (6 Months [168 to 196 Days] After Visit 1) PAGEREF _Toc68776545 \\h 61', '894 unscheduled visits': '8.9.4. Unscheduled Visits PAGEREF _Toc68776546 \\h 61', '9 statistical considerations': '9. STATISTICAL CONSIDERATIONS PAGEREF _Toc68776547 \\h 62', '91 statistical hypotheses': '9.1. Statistical Hypotheses PAGEREF _Toc68776548 \\h 62', '911 estimands': '9.1.1. Estimands PAGEREF _Toc68776549 \\h 62', '92 analysis sets': '9.2. Analysis Sets PAGEREF _Toc68776550 \\h 63', '93 statistical analyses': '9.3. Statistical Analyses PAGEREF _Toc68776551 \\h 64', '931 general considerations': '9.3.1. General Considerations PAGEREF _Toc68776552 \\h 64', '9311 analysis for binary data': '9.3.1.1. Analysis for Binary Data PAGEREF _Toc68776553 \\h 64', '9312 analysis for continuous data': '9.3.1.2. Analysis for Continuous Data PAGEREF _Toc68776554 \\h 64', '932 primary endpointsestimands analysis': '9.3.2. Primary Endpoint(s)/Estimand(s) Analysis PAGEREF _Toc68776555 \\h 65', '933 secondary endpointsestimands analysis': '9.3.3. Secondary Endpoint(s)/Estimand(s) Analysis PAGEREF _Toc68776556 \\h 65', '934 tertiaryexploratory endpoints': '9.3.4. Tertiary/Exploratory Endpoint(s) PAGEREF _Toc68776557 \\h 66', '94 interim analyses': '9.4. Interim Analyses PAGEREF _Toc68776558 \\h 66', '941 analysis timing': '9.4.1. Analysis Timing PAGEREF _Toc68776559 \\h 66', '95 sample size determination': '9.5. Sample Size Determination PAGEREF _Toc68776560 \\h 67', '10 supporting documentation and operational considerations': '10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS PAGEREF _Toc68776561 \\h 68', '101 appendix 1 regulatory ethical and study oversight considerations': '10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations PAGEREF _Toc68776562 \\h 68', '1011 regulatory and ethical considerations': '10.1.1. Regulatory and Ethical Considerations PAGEREF _Toc68776563 \\h 68', '10111 reporting of safety issues and serious breaches of the protocol or ich gcp': '10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP PAGEREF _Toc68776564 \\h 68', '1012 financial disclosure': '10.1.2. Financial Disclosure PAGEREF _Toc68776565 \\h 69', '1013 informed consent process': '10.1.3. Informed Consent Process PAGEREF _Toc68776566 \\h 69', '1014 data protection': '10.1.4. Data Protection PAGEREF _Toc68776567 \\h 70', '1015 committees structure': '10.1.5. Committees Structure PAGEREF _Toc68776568 \\h 70', '10151 data monitoring committee': '10.1.5.1. Data Monitoring Committee PAGEREF _Toc68776569 \\h 70', '1016 dissemination of clinical study data': '10.1.6. Dissemination of Clinical Study Data PAGEREF _Toc68776570 \\h 70', '1017 data quality assurance': '10.1.7. Data Quality Assurance PAGEREF _Toc68776571 \\h 72', '1018 source documents': '10.1.8. Source Documents PAGEREF _Toc68776572 \\h 73', '1019 study and site start and closure': '10.1.9. Study and Site Start and Closure PAGEREF _Toc68776573 \\h 73', '10110 publication policy': '10.1.10. Publication Policy PAGEREF _Toc68776574 \\h 74', '10111 sponsors qualified medical personnel': '10.1.11. Sponsor’s Qualified Medical Personnel PAGEREF _Toc68776575 \\h 75', '102 appendix 2 clinical laboratory tests': '10.2. Appendix 2: Clinical Laboratory Tests PAGEREF _Toc68776576 \\h 76', '103 appendix 3 adverse events definitions and procedures for recording evaluating followup and reporting': '10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, FollowUp, and Reporting PAGEREF _Toc68776577 \\h 77', '1031 definition of ae': '10.3.1. Definition of AE PAGEREF _Toc68776578 \\h 77', '1032 definition of an sae': '10.3.2. Definition of an SAE PAGEREF _Toc68776579 \\h 78', '1033 recordingreporting and followup of aes andor saes during the active collection period': '10.3.3. Recording/Reporting and FollowUp of AEs and/or SAEs During the Active Collection Period PAGEREF _Toc68776580 \\h 80', '1034 reporting of saes': '10.3.4. Reporting of SAEs PAGEREF _Toc68776581 \\h 83', '104 appendix 4 contraceptive and barrier guidance': '10.4. Appendix 4: Contraceptive and Barrier Guidance PAGEREF _Toc68776582 \\h 85', '1041 male participant reproductive inclusion criteria': '10.4.1. Male Participant Reproductive Inclusion Criteria PAGEREF _Toc68776583 \\h 85', '1042 female participant reproductive inclusion criteria': '10.4.2. Female Participant Reproductive Inclusion Criteria PAGEREF _Toc68776584 \\h 85', '1043 woman of childbearing potential': '10.4.3. Woman of Childbearing Potential PAGEREF _Toc68776585 \\h 85', '1044 contraception methods': '10.4.4. Contraception Methods PAGEREF _Toc68776586 \\h 86', '105 appendix 5 liver safety suggested actions and followup assessments': '10.5. Appendix 5: Liver Safety: Suggested Actions and FollowUp Assessments PAGEREF _Toc68776587 \\h 88', '106 appendix 6 aes ades saes sades usades and device deficiencies definitions and procedures for recording evaluating followup and reporting in medical device studies': '10.6. Appendix 6: AEs, ADEs, SAEs, SADEs, USADEs, and Device Deficiencies: Definitions and Procedures for Recording, Evaluating, FollowUp, and Reporting in Medical Device Studies PAGEREF _Toc68776588 \\h 90', '1061 definition of ae and ade': '10.6.1. Definition of AE and ADE PAGEREF _Toc68776589 \\h 90', '1062 definition of sae sade and usade': '10.6.2. Definition of SAE, SADE, and USADE PAGEREF _Toc68776590 \\h 90', '1063 definition of device deficiency': '10.6.3. Definition of Device Deficiency PAGEREF _Toc68776591 \\h 91', '1064 recordingreporting and followup of medical device deficiencies': '10.6.4. Recording/Reporting and Follow-Up of Medical Device Deficiencies PAGEREF _Toc68776592 \\h 91', '1065 reporting of saes': '10.6.5. Reporting of SAEs PAGEREF _Toc68776593 \\h 93', '1066 reporting of sades': '10.6.6. Reporting of SADEs PAGEREF _Toc68776594 \\h 93', '107 appendix 7 alternative measures during public emergencies': '10.7. Appendix 7:  Alternative Measures During Public Emergencies PAGEREF _Toc68776595 \\h 94', '1071 telehealth visits': '10.7.1. Telehealth Visits PAGEREF _Toc68776596 \\h 94', '1072 home health visits': '10.7.2. Home Health Visits PAGEREF _Toc68776597 \\h 94', '1073 adverse events and serious adverse events': '10.7.3. Adverse Events and Serious Adverse Events PAGEREF _Toc68776598 \\h 95', '108 appendix 8 abbreviations': '10.8. Appendix 8: Abbreviations PAGEREF _Toc68776599 \\h 96', '109 appendix 9 criteria for allowing inclusion of participants with chronic stable hiv or hbv infection or cured hcv infection': '10.9. Appendix 9: Criteria for Allowing Inclusion of Participants With Chronic Stable HIV or HBV Infection or Cured HCV Infection PAGEREF _Toc68776600 \\h 99', '11 references': '11. References PAGEREF _Toc68776601 \\h 100', 'table1grading scales for local reactions': 'Table\xa01.Grading Scales for Local Reactions PAGEREF _Toc68776602 \\h 46', 'table 2grading scales for systemic events': 'Table 2.Grading Scales for Systemic Events PAGEREF _Toc68776603 \\h 47', 'table 3ranges for fever': 'Table 3.Ranges for Fever PAGEREF _Toc68776604 \\h 48', 'table 4probability of detecting at least 1 ae': 'Table 4.Probability of Detecting at Least 1 AE PAGEREF _Toc68776605 \\h 67', 'appendix 8': 'Appendix 8', 'appendix4': 'Appendix\xa04', 'appendix 4': 'Appendix 4', 'appendix 1': 'Appendix 1', 'soa': 'SoA', 'appendix 3': 'Appendix 3', 'appendix6': 'Appendix\xa06', 'appendix3': 'Appendix\xa03', 'ref ref21414371 r h mergeformat 834': 'REF _Ref21414371 \\r \\h  \\* MERGEFORMAT 8.3.4'}NORMALIZED TEXT NORMALIZED TEXT NORMALIZED TEXT a phase3 randomized doubleblind trial to describe the safety and immunogenicity of 20valent pneumococcal conjugate vaccine when coadministered with a booster dose of bnt162b2 in adults 65years of age and olderNORMALIZED TEXT NORMALIZED TEXT NORMALIZED TEXT document historyNORMALIZED TEXT NORMALIZED TEXT NORMALIZED TEXT table of contentsNORMALIZED TEXT list of tables8NORMALIZED TEXT 1 protocol summary9NORMALIZED TEXT 11 synopsis9NORMALIZED TEXT 12 schema13NORMALIZED TEXT 13 schedule of activities14NORMALIZED TEXT 2 introduction16NORMALIZED TEXT 21 pneumococcal disease16NORMALIZED TEXT 22 vaccines to prevent pneumococcal disease16NORMALIZED TEXT 221 pneumococcal polysaccharide vaccines16NORMALIZED TEXT 222 pneumococcal polysaccharide conjugate vaccines17NORMALIZED TEXT 23 development of 20vpnc18NORMALIZED TEXT 24 indication19NORMALIZED TEXT 25 coronavirus disease 2019 covid1919NORMALIZED TEXT 26 study rationale20NORMALIZED TEXT 27 background20
